Abilify MyCite (aripiprazole): Withdrawal of the marketing authorisation application for use in schizophrenia and manic episodes of bipolar disorder

This drug/device combination included an ingestible sensor which assisted in monitoring adherence. The CHMP had previously concluded that the benefits of the product did not outweigh the risks, and the manufacturer could not currently resolve these concerns.

European Medicines Agency